TCM
ANAB icon

Tekla Capital Management’s AnaptysBio ANAB Stock Holding History

Tekla Capital Management’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-118,261
Closed -$2.64M – 206
2020
Q2 		$2.64M Hold
118,261
– – 0.1% 147
2020
Q1 		$1.67M Hold
118,261
– – 0.08% 146
2019
Q4 		$1.92M Buy
118,261
+50,765
+75% +$1.2M 0.07% 153
2019
Q3 		$2.36M Sell
67,496
-7,302
-10% -$347K 0.1% 130
2019
Q2 		$4.22M Buy
74,798
+8,953
+14% +$645K 0.17% 100
2019
Q1 		$4.81M Hold
65,845
– – 0.2% 97
2018
Q4 		$4.2M Buy
65,845
+19,935
+43% +$1.48M 0.18% 94
2018
Q3 		$4.58M Buy
+45,910
New +$3.81M 0.17% 98

Other funds holding ANAB

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Tekla Capital Management's ANAB Position: Q3 2020 in Review

Tekla Capital Management sold out of AnaptysBio (ANAB) in Q3 2020, closing a stake of 118,261 shares — an estimated $2.64M sold.

Tekla Capital Management first reported a position in ANAB in Q3 2018 and held it in 8 quarters. The position peaked at $4.81M in Q1 2019. 132 funds tracked by Wall St. Rank hold ANAB as of Q3 2020.

  • Tekla Capital Management reported no remaining AnaptysBio position as of Q3 2020 after selling out during the quarter.
  • Tekla Capital Management sold 118,261 AnaptysBio shares in Q3 2020, an estimated $2.64M.
  • Tekla Capital Management first reported a position in AnaptysBio in Q3 2018 and held it in 8 quarters.
  • Tekla Capital Management's AnaptysBio position peaked at $4.81M in Q1 2019.
  • 132 funds tracked by Wall St. Rank held AnaptysBio as of Q3 2020.

Based on Tekla Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.